{
  "id": 10732482,
  "title": "Iovance Biotherapeutics Stock Rises 33% After Raising FY26 Total Revenue Outlook",
  "url": "https://urgent.news/2026/09/29/iovance-biotherapeutics-stock-rises-33-after-raising-fy26-total",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T16:26:11.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/iovance-biotherapeutics-stock-rises-33-after-raising-fy26-total-revenue-outlook"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Shares of Iovance Biotherapeutics, Inc. (IOVA) are gaining about 33 percent on Tuesday morning after the company announced its decision to raise its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi and Prole",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}